Lantern Pharma Inc. — Form 8-K
Filed September 30, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 12/100
What the filing says
On September 28, 2026, Lantern Pharma Inc. issued approximately $4 million in common stock and warrants to multiple accredited investors via registered offering (Form S-3). The deal included: direct common shares at $1.09/share; prefunded warrants exercisable immediately at $0.0001/share; and standard warrants exercisable at $1.09/share after stockholder approval, with 5-year term. Rodman Renshaw LLC acted as placement agent. Settlement on September 30, 2026.
Why this rating
~$4M capital raise ≈12% of company's $33.9M market cap. Routine financing for micro-cap biotech; standard terms, registered offering.
See more from September 30, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.